Alana L. Welm, PhD

Research Interests

  • Breast Cancer
  • Neoplasm Metastasis
  • Tumor Immunology


Lab Website


  • English

Academic Information

  • Departments: Oncological Sciences - Professor
  • Cancer Center Programs: Cell Response & Regulation

Academic Office Information

  • Huntsman Cancer Institute
    2000 Circle of Hope
    Salt Lake City, UT 84112

Academic Bio

Alana Welm, PhD, is an Associate Professor in the Department of Oncological Sciences at the University of Utah, an Investigator at the Huntsman Cancer Institute, and Co-Leader of the Cell Response and Regulation Program at HCI. Welm's laboratory studies breast cancer metastasis.

Dr. Welm completed her PhD in Cell and Molecular Biology at Baylor College of Medicine in Houston, TX under the supervision of Gretchen Darlington, PhD. She then went on to conduct postdoctoral training in Dr. J. Michael Bishop’s laboratory at the University of California, San Francisco where her work focused on developing new models of breast cancer metastasis. Dr. Welm started her laboratory at the University of Utah’s Huntsman Cancer Institute in 2007, and was promoted to Associate Professor with tenure in 2013.

The research in Dr. Welm’s laboratory is focused on solving the problem of breast cancer metastasis using in vivo modeling of mouse and human breast cancers. Dr. Welm’s group discovered that the Ron kinase pathway is an important facilitator of breast cancer metastasis through its unique dual function in tumor cells and in resident macrophages. Current areas of research include (1) pre-clinical studies of various Ron inhibitors for treatment and prevention of metastatic breast cancer; (2) pre-clinical and early clinical studies of Ron/Met inhibitors in bone metastatic cancers; (3) discovering molecular mechanisms by which Ron kinases promote metastasis through cell-autonomous and non cell-autonomous pathways; and (4) refining “precision medicine” for metastatic breast cancer using functional assays in patient-derived breast tumor grafts.

Education History

Type School Degree
Postdoctoral Fellowship University of California, San Francisco
Cancer Biology
Postdoctoral Fellow
Doctoral Training Baylor College of Medicine
Cell and Molecular Biology
Undergraduate University of Montana

Selected Publications

Journal Article

  1. Sun Q, Lesperance J, Wettersten H, Luterstein E, DeRose YS, Welm A, Cheresh DA, Desgrosellier JS (2018 Jan 2). Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis. J Clin Invest, 128(1), 531-544.
  2. Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, Gu Z, Wiser JA, Dunn P, Begley DA, Krupke DM, Bertotti A, Bruna A, Brush MH, Byrne AT, Caldas C, Christie AL, Clark DA, Dowst H, Dry JR, Doroshow JH, Duchamp O, Evrard YA, Ferretti S, Frese KK, Goodwin NC, Greenawalt D, Haendel MA, Hermans E, Houghton PJ, Jonkers J, Kemper K, Khor TO, Lewis MT, Lloyd KCK, Mason J, Medico E, Neuhauser SB, Olson JM, Peeper DS, Rueda OM, Seong JK, Trusolino L, Vinolo E, Wechsler-Reya RJ, Weinstock DM, Welm A, Weroha SJ, Amant F, Pfister SM, Kool M, Parkinson H, Butte AJ, Bult CJ (2017 Nov 1). PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. Cancer Res, 77(21), e62-e66.
  3. Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, Welm A, Antonyak MA, Cerione RA (2017 Feb 16). A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun, 8, 14450.
  4. Lloyd IE, Welm AL, DeRose Y, Neumayer LA, Kohan JL, Malmberg EM, Salama ME, Factor RE (2017 Feb 9). X-Ray of Excised Cancerous Breast Tissue Does Not Affect Clinical Biomarker Expression.LID - 10.1097/PAI.0000000000000454 [doi]. (Epub ahead of print) Appl Immunohistochem Mol Morphol.
  5. Olsen SN, Wronski A, Castano Z, Dake B, Malone C, De Raedt T, Enos M, DeRose YS, Zhou W, Guerra S, Loda M, Welm A, Partridge AH, McAllister SS, Kuperwasser C, Cichowski K (2017 Feb). Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. Cancer Discov, 7(2), 202-217.
  6. Andrade K, Fornetti J, Zhao L, Miller SC, Randall RL, Anderson N, Waltz SE, McHale M, Welm AL (2017 Jan 25). RON kinase: A target for treatment of cancer-induced bone destruction and osteoporosis.LID - eaai9338 [pii]LID - 10.1126/scitranslmed.aai9338 [doi]. Sci Transl Med, 9(374).
  7. Bruna A, Rueda OM, Greenwood W, Batra AS, Callari M, Batra RN, Pogrebniak K, Sandoval J, Cassidy JW, Tufegdzic-Vidakovic A, Sammut SJ, Jones L, Provenzano E, Baird R, Eirew P, Hadfield J, Eldridge M, McLaren-Douglas A, Barthorpe A, Lightfoot H, OConnor MJ, Gray J, Cortes J, Baselga J, Marangoni E, Welm AL, Aparicio S, Serra V, Garnett MJ, Caldas C (2016 Sep 22). A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 167(1), 260-274.e22.
  8. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ (2016 Sep 8). Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res, 18(1), 90.
  9. Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin A, Welm AL, Oesterreich S, Sikora MJ, Brown RE, Mills GB (2016 May 12). High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype.LID - clincanres.0171.2016 [pii]. (Epub ahead of print) Clin Cancer Res.
  10. Moxley KM, Wang L, Welm AL, Bieniasz M (2016 May). Short-form Ron is a novel determinant of ovarian cancer initiation and progression. Genes Cancer, 7(5-6), 169-81.
  11. Giro-Perafita A, Palomeras S, Lum D, Blancafort A, Vinas G, Oliveras G, Perez-Bueno F, Sarrats A, Welm AL, Puig T (2016 Apr 22). Preclinical Evaluation of Fatty Acid Synthase and EGFR Inhibition in Triple Negative Breast Cancer.LID - clincanres.3133.2016 [pii]. (Epub ahead of print) Clin Cancer Res.
  12. Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL (2015 Dec 15). Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res, 21(24), 5588-600.
  13. Shen L, OShea JM, Kaadige MR, Cunha S, Wilde BR, Cohen AL, Welm AL, Ayer DE (2015 Apr 28). Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. Proc Natl Acad Sci U S A, 112(17), 5425-30.
  14. Chaturvedi A, Hoffman LM, Jensen CC, Lin YC, Grossmann AH, Randall RL, Lessnick SL, Welm AL, Beckerle MC (2014 Sep 15). Molecular dissection of the mechanism by which EWS/FLI expression compromises actin cytoskeletal integrity and cell adhesion in Ewing sarcoma. Mol Biol Cell, 25(18), 2695-709.
  15. Sikora MJ, Cooper KL, Bahreini A, Luthra S, Wang G, Chandran UR, Davidson NE, Dabbs DJ, Welm AL, Oesterreich S (2014 Mar 1). Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res, 74(5), 1463-74.
  16. Cunha S, Lin YC, Goossen EA, DeVette CI, Albertella MR, Thomson S, Mulvihill MJ, Welm AL (2014 Jan 16). The RON receptor tyrosine kinase promotes metastasis by triggering MBD4-dependent DNA methylation reprogramming. Cell Rep, 6(1), 141-54.
  17. Eyob H, Ekiz HA, Welm AL (2013 Sep 1). RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses. Oncoimmunology, 2(9), e25670.
  18. McKenzie JA, Liu T, Jung JY, Jones BB, Ekiz HA, Welm AL, Grossman D (2013 Sep). Survivin promotion of melanoma metastasis requires upregulation of alpha5 integrin. Carcinogenesis, 34(9), 2137-44.
  19. Eyob H, Ekiz HA, Derose YS, Waltz SE, Williams MA, Welm AL (2013 Jul). Inhibition of ron kinase blocks conversion of micrometastases to overt metastases by boosting antitumor immunity. Cancer Discov, 3(7), 751-60.
  20. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, Wiegmans AP, Swarbrick A, Welm AL, Brown MP, Chenevix-Trench G, Lakhani SR, Khanna KK (2013 Jun). Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med, 54(6), 913-21.
  21. DeRose YS, Gligorich KM, Wang G, Georgelas A, Bowman P, Courdy SJ, Welm AL, Welm BE (2013 Mar). Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol, Chapter 14, Unit14.23.
  22. Lum DH, Matsen C, Welm AL, Welm BE (2012 Dec). Overview of human primary tumorgraft models: comparisons with traditional oncology preclinical models and the clinical relevance and utility of primary tumorgrafts in basic and translational oncology research. Curr Protoc Pharmacol, Chapter 14, Unit 14.22.
  23. Tsai HC, Li H, Van Neste L, Cai Y, Robert C, Rassool FV, Shin JJ, Harbom KM, Beaty R, Pappou E, Harris J, Yen RW, Ahuja N, Brock MV, Stearns V, Feller-Kopman D, Yarmus LB, Lin YC, Welm AL, Issa JP, Minn I, Matsui W, Jang YY, Sharkis SJ, Baylin SB, Zahnow CA (2012 Mar 20). Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell, 21(3), 430-46.
  24. Chaturvedi A, Hoffman LM, Welm AL, Lessnick SL, Beckerle MC (2012 Feb). The EWS/FLI Oncogene Drives Changes in Cellular Morphology, Adhesion, and Migration in Ewing Sarcoma. Genes Cancer, 3(2), 102-16.
  25. Larrieu-Lahargue F, Welm AL, Bouchecareilh M, Alitalo K, Li DY, Bikfalvi A, Auguste P (2012). Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. PLoS ONE, 7(6), e39540.
  26. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, Welm AL (2011 Oct 23). Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat Med, 17(11), 1514-20.
  27. Larrieu-Lahargue F, Welm AL, Thomas KR, Li DY (2011 Sep 16). Netrin-4 activates endothelial integrin {alpha}6{beta}1. Circ Res, 109(7), 770-4.
  28. Powers MA, Fay MM, Factor RE, Welm AL, Ullman KS (2011 Aug 15). Protein arginine methyltransferase 5 accelerates tumor growth by arginine methylation of the tumor suppressor programmed cell death 4. Cancer Res, 71(16), 5579-87.
  29. Liu X, Zhao L, Derose YS, Lin YC, Bieniasz M, Eyob H, Buys SS, Neumayer L, Welm AL (2011 Jul). Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase. Genes Cancer, 2(7), 753-62.
  30. Larrieu-Lahargue F, Welm AL, Thomas KR, Li DY (2010 Jul 1). Netrin-4 induces lymphangiogenesis in vivo. Blood, 115(26), 5418-26.
  31. Kim S, Welm AL, Bishop JM (2010 Jun 15). A dominant mutant allele of the ING4 tumor suppressor found in human cancer cells exacerbates MYC-initiated mouse mammary tumorigenesis. Cancer Res, 70(12), 5155-62.
  32. Gilbert PM, Mouw JK, Unger MA, Lakins JN, Gbegnon MK, Clemmer VB, Benezra M, Licht JD, Boudreau NJ, Tsai KK, Welm AL, Feldman MD, Weber BL, Weaver VM (2010 May). HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J Clin Invest, 120(5), 1535-50.
  33. Micalizzi DS, Christensen KL, Jedlicka P, Coletta RD, Baron AE, Harrell JC, Horwitz KB, Billheimer D, Heichman KA, Welm AL, Schiemann WP, Ford HL (2009 Sep). The Six1 homeoprotein induces human mammary carcinoma cells to undergo epithelial-mesenchymal transition and metastasis in mice through increasing TGF-beta signaling. J Clin Invest, 119(9), 2678-90.
  34. McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL (2009 Sep). Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest, 119(9), 2663-77.
  35. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM (2009 Apr 1). Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res, 15(7), 2311-22.
  36. Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z (2008 Jan 10). Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell, 2(1), 90-102.
  37. Bhatt AS, Welm A, Farady CJ, Vasquez M, Wilson K, Craik CS (2007 Apr 3). Coordinate expression and functional profiling identify an extracellular proteolytic signaling pathway. Proc Natl Acad Sci U S A, 104(14), 5771-6.
  38. Welm AL, Sneddon JB, Taylor C, Nuyten DSA, Van de Vijer MJ, Hasegawa BH, Bishop JM (2007). The macrophage stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans. Proc Natl Acad Sci U S A, 104(18), 7570-7575.
  39. Welm AL, Kim S, Welm BE, Bishop JM (2005 Mar 22). MET and MYC cooperate in mammary tumorigenesis. Proc Natl Acad Sci U S A, 102(12), 4324-9.
  40. Yang D, Welm A, Bishop JM (2004 Oct 19). Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A, 101(42), 15100-5.
  41. Timchenko LT, Iakova P, Welm AL, Cai ZJ, Timchenko NA (2002 Oct). Calreticulin interacts with C/EBPalpha and C/EBPbeta mRNAs and represses translation of C/EBP proteins. Mol Cell Biol, 22(20), 7242-57.
  42. Welm AL, Timchenko NA, Ono Y, Sorimachi H, Radomska HS, Tenen DG, Lekstrom-Himes J, Darlington GJ (2002 Sep 13). C/EBPalpha is required for proteolytic cleavage of cyclin A by calpain 3 in myeloid precursor cells. J Biol Chem, 277(37), 33848-56.
  43. Wang H, Iakova P, Wilde M, Welm A, Goode T, Roesler WJ, Timchenko NA (2001 Oct). C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell, 8(4), 817-28.
  44. Timchenko NA, Cai ZJ, Welm AL, Reddy S, Ashizawa T, Timchenko LT (2001 Mar 16). RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem, 276(11), 7820-6.
  45. Welm AL, Mackey SL, Timchenko LT, Darlington GJ, Timchenko NA (2000 Sep 1). Translational induction of liver-enriched transcriptional inhibitory protein during acute phase response leads to repression of CCAAT/enhancer binding protein alpha mRNA. J Biol Chem, 275(35), 27406-13.
  46. Timchenko NA, Welm AL, Lu X, Timchenko LT (1999 Nov 15). CUG repeat binding protein (CUGBP1) interacts with the 5' region of C/EBPbeta mRNA and regulates translation of C/EBPbeta isoforms. Nucleic Acids Res, 27(22), 4517-25.
  47. Welm AL, Timchenko NA, Darlington GJ (1999 Mar). C/EBPalpha regulates generation of C/EBPbeta isoforms through activation of specific proteolytic cleavage. Mol Cell Biol, 19(3), 1695-704.
  48. Sonia Palomeras, Angel Diaz-Lagares, Gemma Vias, Fernando Setien, Humberto J Ferreira, Glria Oliveras, Ana Belen Crujeiras, Alejandro Hernndez, David Lum, Alana Welm, Manel Esteller, and Teresa Puig (). Epigenetic Silencing of TGFBI Confers Resistance to Trastuzumab in Human Breast Cancer. Clin Cancer Res.


  1. Dobrolecki LE, Airhart SD, Alferez DG, Aparicio S, Behbod F, Bentires-Alj M, Brisken C, Bult CJ, Cai S, Clarke RB, Dowst H, Ellis MJ, Gonzalez-Suarez E, Iggo RD, Kabos P, Li S, Lindeman GJ, Marangoni E, McCoy A, Meric-Bernstam F, Piwnica-Worms H, Poupon MF, Reis-Filho J, Sartorius CA, Scabia V, Sflomos G, Tu Y, Vaillant F, Visvader JE, Welm A, Wicha MS, Lewis MT (2016 Dec). Patient-derived xenograft (PDX) models in basic and translational breast cancer research. [Review]. Cancer Metastasis Rev, 35(4), 547-573.
  2. Faham N, Welm AL (2016). RON Signaling Is a Key Mediator of Tumor Progression in Many Human Cancers. [Review]. Cold Spring Harb Symp Quant Biol, 81, 177-188.
  3. Kretschmann KL, Welm AL (2012 Dec). Mouse models of breast cancer metastasis to bone. [Review]. Cancer Metastasis Rev, 31(3-4), 579-83.
  4. Smith BA, Welm AL, Welm BE (2012 Jul). On the shoulders of giants: a historical perspective of unique experimental methods in mammary gland research. [Review]. Semin Cell Dev Biol, 23(5), 583-90.
  5. Lum D, Matsen C, Welm AL, Welm BE (). Human primary tumor graft models: their clinical relevance and utility in basic and translational oncology research. [Review]. Curr Protoc Pharmacol, Chapter 14(Unit 14), 22.
  6. Kretschmann KL, Eyob H, Buys SS, Welm AL (2010 Sep). The macrophage stimulating protein/Ron pathway as a potential therapeutic target to impede multiple mechanisms involved in breast cancer progression. [Review]. Curr Drug Targets, 11(9), 1157-68.
  7. Welm AL (2008 Apr 4). TGFbeta primes breast tumor cells for metastasis. [Review]. Cell, 133(1), 27-8.

Book Chapter

  1. Hill WE, Bucklin DJ, Bullard JM, Galbraith AL, Jammi NV, Rettburg CC, Sawyer BS, Van Waes MA (1995). Identification of ribosome-ligand interactions using cleavage reagents. In Frontiers in Translation Biochem. Cell. Biol (73, pp. 1033-1039).

Conference Proceedings

  1. Welm AL (2003). AACR Special Conference: Advances in Breast Cancer Research- Genetics, Biology, and Clinical Implications. Breast Cancer Res, Huntington Beach, 6, E6.


  1. Matthew J Sikora, Uma R Chandran, David J Dabbs, Alana L Welm, and Steffi Oesterreich (). Endocrine resistance in invasive lobular carcinoma cells parallels unique estrogen-mediated gene expression. San Antonio Breast Cancer Symposium, San Antonio, TX [Abstract].
  2. DeRose YS, Wang G, Lin Y-C, Bernard PS, Buys SS, Ebbert MTW, Factor R, Matsen C, Milash BA, Nelson E, Neumayer L, Randall RL, Stijleman IJ, Welm BE, and Welm AL (). Patient-derived tumor grafts authentically reflect tumor pathology, growth, metastasis, and disease outcomes. American Association for Cancer Research Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Francisco, CA [Abstract].
  3. Chaturvedi AP, Welm AL, Lessnick SL, and Beckerle MC (). Impact of EWS-FLI induced changes in gene expression and cell behavior for metastatic potential. AACR Annual Meeting, Washington, D.C [Abstract].
  4. Kretschmann, K, Waltz S, and Welm AL (). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. DOD Era of Hope Breast Cancer Conference, Orlando, FL [Abstract].
  5. Kretschmann, K, Waltz S, and Welm AL (). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. Gordon Conference on Mammary Gland Biology, Barga, Italy [Abstract].
  6. Eyob, H, Waltz, S, and Welm, AL (). Elucidating the mechanism of MSP-mediated breast cancer metastasis. Cold Spring Harbor conference on The Biology of Cancer: Microenvironment, Metastasis and Therapeutics, Cold Spring Harbor, NY [Abstract].
  7. Eyob H, Kretschmann K, Waltz S, and Welm AL (). Mechanisms of breast cancer metastasis that are extrinsic to tumor cells. Joint Metastasis Research Society-AACR Conference on Metastasis, Philadelphia, PA [Abstract].
  8. Farabaugh S, Micalizzi D, Welm AL, and Ford H (). The Six1 homeoprotein is dependent on Eya2 to mediate TGF¿ signaling, EMT properties, and stem cell characteristics in breast cancer. Joint Metastasis Research Society-AACR Conference on Metastasis, Philadelphia, PA [Abstract].
  9. Eyob, H, Waltz, S, and Welm, AL (). Elucidating the mechanism of MSP-mediated breast cancer metastasis. American Association for Cancer Research Special Conference on Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Diego, CA [Abstract].
  10. Ching Hang Wong, Frederick L Baehner, Danislav S Spassov, Deepika Ahuja, Donghui Wang, Byron Hann, Jimmy Blair, Kevan Shokat, Alana L Welm, Mark M Moasser (). Trask, a new biomarker of epithelial tumors with increased src kinase activity. 100th Annual American Association for Cancer Research Meeting, Denver, CO [Abstract].
  11. Douglas S Micalizzi, Kimberly L Christensen, Paul Jedlicka, Dean Billheimer, Alana L Welm, William P Schiemann, Heide L Ford (). The six1 homeoprotein induces transforming growth factor-¿ signaling, epithelial to mesenchymal transition, and breast cancer metastasis. 100th Annual American Association for Cancer Research Meeting, Denver, CO [Abstract].
  12. Kretschmann, K, Waltz S, Welm AL (). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone. Cancer and Bone Society International Meeting, Sydney, Australia [Abstract].
  13. Chong, C, Maddox, J, Welm AL (). Macrophage-stimulating protein promotes cell invasion in vitro through an epithelial-mesenchymal transitionI. 100th Annual American Association for Cancer Research Meeting, Denver, CO [Abstract].
  14. Heide L Ford, Chu-An Wang, Kimberly Christensen, Douglas Micalizzi, J Chuck Harrell, Kathryn Horwitz, Karen Heichman, Alana Welm, Paul Jedlicka (). The six1 homeobox gene regulates lymphoangiogenesis and metastasis in a mouse model of breast cancer. 100th Annual American Association for Cancer Research Meeting, Denver, CO [Abstract].
  15. Cecinio Ronquillo Jr, Alana L Welm (). Macrophage stimulating protein may transiently increase a population of ALDH1A1high cells which in turn may be correlated to breast cancer cell lines’ tumorignicity and metastatic potential. 100th Annual American Association for Cancer Research Meeting, Denver, CO [Abstract].
  16. Maddox J, Chong CA, Bishop JM, Welm AL (August 6, 2008). The role of Macrophage Stimulating Protein in metastasis of breast cancer to bone [Abstract].
  17. Welm AL, Timchenko NA, Darlington GJ (1999). C/EBPα regulates proteolytic cleavage of C/EBPβ [Abstract]. FASEB J, 13, A1483.


  1. Faculty of 1000 Biology (2007). Highlight on: "The macrophage stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans" by Welm AL, Sneddon JB, Taylor C, Nuyten DSA, Van de Vijer MJ, Hasegawa BH, Bishop JM. Proc. Nat. Acad. Sci. USA (104, pp. 7570-5).
  2. Dell H (2005). Highlight on: "MET and MYC cooperate in mammary tumorigenesis" by Welm AL; Kim S; Welm BE; Bishop JM. Nat Rev Cancer (102, pp. 4324-4329).